Videos

​Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways.

Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin.

Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.

​Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.

Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.

Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

William Sikov, MD, associate director of Clinical Research, Program in Women

Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer.

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.

S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.

Neal Young, MD, discusses the advancement of treatment for aplastic anemia. Young said aplastic anemia used to kill almost all patients diagnosed with the disease within a year.

Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).